Xylem (XYL) EBITDA (2010 - 2026)

Xylem has reported EBITDA for 17 years, with the latest figure at $390.0 million in Q2 2026.

• On a quarterly basis, EBITDA rose 27.87% year-over-year to $390.0 million in Q2 2026; TTM through Jun 2026 was $1.3 billion, a 21.98% increase from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 21.21% from the prior year.
• EBITDA was $390.0 million for Q2 2026 at Xylem, up from $244.0 million in the prior quarter.
• The five-year high for EBITDA was $390.0 million in Q2 2026, with the low at $111.0 million in Q1 2022.
• Average EBITDA over 5 years is $230.0 million, with a median of $221.0 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: EBITDA retreated 18.49% in 2023, then surged 112.61% in 2024.
• Over 5 years, EBITDA stood at $197.0 million in 2022, then rose by 7.11% to $211.0 million in 2023, then gained by 26.54% to $267.0 million in 2024, then jumped by 32.21% to $353.0 million in 2025, then grew by 10.48% to $390.0 million in 2026.
• The last three EBITDA figures came in at $390.0 million (Q2 2026), $244.0 million (Q1 2026), and $353.0 million (Q4 2025), per Business Quant data.